PDPaul Devroey

Paul Devroey

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Paul Devroey has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Anti-Müllerian hormone for the assessment of ovarian response in GnRH-antagonist-treated oocyte donors

    by Nikolaos P. Polyzos, Dominic Stoop, Christophe Blockeel, Paul Adriaensen, Peter Platteau, Ellen Anckaert, Johan Smitz, Paul Devroey


  • Open Access

    Obstetric outcome in donor oocyte pregnancies: a matched-pair analysis

    by Dominic Stoop, Miriam Baumgarten, Patrick Haentjens, Nikolaos P Polyzos, Michel De Vos, Greta Verheyen, Michel Camus, Paul Devroey

    To investigate the obstetrical and perinatal impact of oocyte donation, a cohort of women who conceived after OD was compared with a matched control group of women who became pregnant through in vitro fertilisation with autologous oocytes (AO).


  • Top Cited Papers
    Open Access

    An OHSS-Free Clinic by segmentation of IVF treatment

    by Paul Devroey, Nikolaos P. Polyzos, Christophe Blockeel

    Published data indicate a significant increase in ovarian hyperstimulation syndrome globally. The occurrence of approximately three maternal deaths per 100 000 stimulated women has been reported, and extrapolation of these figures to a global situation would give an impressive number. The syndrome can be erased by applying ovarian stimulation using the combination of GnRH antagonist with GnRH agonist to trigger ovulation. In this case, the strategy is to freeze all of the oocytes or embryos for later use.


  • Open Access

    Aromatase inhibitors in post-menopausal endometriosis

    by Nikolaos P Polyzos, Human M Fatemi, Apostolos Zavos, Grigoris Grimbizis, Dimitra Kyrou, Juan-Garcia Velasco, Paul Devroey, Basil Tarlatzis, Evangelos G Papanikolaou

    Postmenopausal endometriosis is a rare clinical condition. The diagnosis and treatment of an endometriotic lesion in postmenopausal women is complicated. First line treatment choice should be surgical, given that there is a potential risk of malignancy. Medical treatment may be considered as second line or as an alternate first line treatment whenever surgery is contradicted and aims to alter the hormonal pathway leading to endometriosis progress. Different hormonal regimens have been administered to these patients, with conflicting however results. Aromatase inhibitors (AIs) represent one of the most recently used drugs for postmenopausal endometriosis. Clinical data for the use of (AIs) in postmenopausal patients is scarce. Up to date only 5 case reports are available regarding the use of these agents in postmenopausal women. Although definite conclusions may be premature, AIs appear to considerably improve patients' symptoms and reduce endometriotic lesions size. Nonetheless the subsequent induced reduction in estrogen production, leads to certain short-term and long-term adverse effects. Despite the limited available data, AIs appear to represent a new promising method which may improve symptoms and treat these patients, either as first line treatment, when surgery is contraindicated or as a second line for recurrences following surgical treatment. However, careful monitoring of patients' risk profile and further research regarding long-term effects and side-effects of these agents is essential prior implementing them in everyday clinical practice.


    • 1 January 2011
      • Vol. 3  (1) , 43-45
    Open Access

    OHSS Free Clinic

    by P. Devroey, P. Adriaensen

    If ovarian stimulation is performed accordingly to new strategies available, the occurrence of ovarian hyperstimulation syndrome will be eradicated. The strategy is to stimulate all women with GnRH antagonist and in case of need to induce final egg maturation with GnRH agonist.


  • Open Access

    Should a single blastocyst transfer policy be a clinical decision or should it depend on the embryological evaluation on day 3?

    by Dominic Stoop, Lisbet Van Landuyt, Etienne Van Den Abbeel, Michel Camus, Greta Verheyen, Paul Devroey

    Single blastocyst transfer has the advantage of maximizing the fresh single pregnancy rate. However, in patients with a low number of good quality embryos on day 3, it remains unclear whether immediate embryo transfer or further embryo culture with blastocyst transfer is the most preferable option.


  • Open Access

    Approaches to improve the diagnosis and management of infertility

    by P. Devroey, B.C.J.M. Fauser, K. Diedrich

    Recent advances in our understanding of the causes of infertility and of assisted reproductive technology (ART) have led to the development of complex diagnostic tools, prognostic models and treatment options. The Third Evian Annual Reproduction (EVAR) Workshop Meeting was held on 26–27 April 2008 to evaluate evidence supporting current approaches to the diagnosis and management of infertility and to identify areas for future research efforts. Specialist reproductive medicine clinicians and scientists delivered presentations based on published literature and ongoing research on patient work-up, ovarian stimulation and embryo quality assessment during ART. This report is based on the expert presentations and subsequent group discussions and was supplemented with publications from literature searches and the authors' knowledge. It was agreed that single embryo transfer (SET) should be used with increasing frequency in cycles of ART. Continued improvements in cryopreservation techniques, which improve pregnancy rates using supernumerary frozen embryos, are expected to augment the global uptake of SET. Adaptation and personalization of fertility therapy may help to optimize efficacy and safety outcomes for individual patients. Prognostic modelling and personalized management strategies based on individual patient characteristics may prove to represent real progress towards improved treatment. However, at present, there is limited good-quality evidence to support the use of these individualized approaches. Greater quality control and standardization of clinical and laboratory evaluations are required to optimize ART practices and improve individual patient outcomes. Well-designed, good-quality studies are required to drive improvements to the diagnosis and management of ART processes.


  • Open Access

    Improving the patient's experience of IVF/ICSI: a proposal for an ovarian stimulation protocol with GnRH antagonist co-treatment

    by Paul Devroey, Mohamed Aboulghar, Juan Garcia-Velasco, Georg Griesinger, Peter Humaidan, Efstratios Kolibianakis, William Ledger, Candido Tomás, Bart C.J.M. Fauser

    Patients undergoing IVF/ICSI frequently experience substantial treatment burden, risk and psychological distress. These three related elements contribute to a negative patient experience that can lead to treatment discontinuation if pregnancy is not achieved. One approach to minimize these factors is the use of protocols designed to achieve high term, singleton birth rates per IVF treatment started, while improving the patient's welfare. Gonadotrophin-releasing hormone (GnRH) antagonists may be suitable for inclusion in such a protocol. In clinical trial data and meta-analyses, treatment with these agents is associated with similar live birth rates but reduced treatment burden (duration and side effects) and less risk of ovarian stimulation syndrome, compared with GnRH agonist long protocols. GnRH antagonists may also be associated with reduced psychological distress compared with agonists, but so far, the evidence for this is inconclusive. To facilitate the implementation of treatments that optimize the patient's experience, a simple GnRH antagonist protocol for use in predicted normal responders is proposed.


  • Open Access

    Ovarian stimulation for in vitro fertilization in patients with endometriosis

    by Kostantinos Zikopoulos, Efstratios M. Kolibianakis, Paul Devroey

    The use of gonadotropin-releasing hormone (GnRH) agonists in a long protocol appears to enhance the probability of conception in the presence of endometriosis. In addition, there is evidence to suggest that the use of prolonged downregulation with GnRH agonists prior to ovarian stimulation for in vitro fertilization (IVF) is beneficial for achieving pregnancy. Until now, GnRH antagonists have not been used in patients with endometriosis. The management of endometriomas prior to stimulation for IVF and its impact on reproductive outcome are still subject to debate.